Attach to Form 990 or Form 990-EZ.
See separate instructions.| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) | (iv) Is the organization in col. (i) listed in your governing document? | (v) Did you notify the organization in col. (i) of your support? | (vi) Is the organization in col. (i) organized in the U.S.? | (vii) Amount of monetary support | |||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Total | |||||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2008 | (b) 2009 | (c) 2010 | (d) 2011 | (e) 2012 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2008 | (b) 2009 | (c) 2010 | (d) 2011 | (e) 2012 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.).. | ||||||
| 11 | Total support (Add lines 7 through 10). | ||||||






Calendar year (or fiscal year beginning in) ![]() |
(a) 2008 | (b) 2009 | (c) 2010 | (d) 2011 | (e) 2012 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2008 | (b) 2009 | (c) 2010 | (d) 2011 | (e) 2012 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||




| Facts And Circumstances Test |
|---|
| Explanation |
|---|
| MULTI-DISCIPLINARY CENTRE OF ONCOLOGY AT THE UNIVERSITY HOSPITAL CENTRE OF THE CANTON VAUD, LAUSANNE, SWITZERLAND. UNIVERSITY CLINIC OF ST. LUC, BRUSSELS, BELGIUM. THE ROYAL MELBOURNE HOSPITAL, MELBOURNE, AUSTRALIA. AUSTIN HEALTH, MELBOURNE, AUSTRALIA. SOCIEDADE BENEFICIENTE DE SENHORAS HOSPITAL SRIO-LIBANS, SAO PAULO, BRAZIL. KAROLINSKA UNIVERSITETSSJUKHUSET, STOCKHOLM, SWEDEN. AKADEMISKA SJUKHUSET, UPPSALA, SWEDEN. MEMORIAL SLOAN-KETTERING CANCER CENTER, NEW YORK, NEW YORK. UNIVERSITY OF CALIFORNIA, SAN DIEGO - SCHOOL OF MEDICINE, SAN DIEGO, CALIFORNIA. |
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.| Identifier | Return Reference | Explanation |
|---|---|---|
| FORM 990, PART III, LINE 3 | THE INSTITUTE IS IN THE PROCESS OF CONSOLIDATING ITS RESEARCH ACTIVITIES AT LARGER BUT FEWER BRANCHES. AS PART OF THIS TRANSITION, NEW SCIENTIFIC GROUPS COMMENCED RESEARCH AT THE OXFORD AND SAN DIEGO BRANCHES. THE SCIENTIFIC ACTIVITIES AT THE MELBOURNE-PARKVILLE BRANCH CEASED DURING 2012. THE SCIENTIFIC STAFF RELOCATED TO THE WALTER AND ELIZA HALL INSTITUTE, MELBOURNE WITH TRANSITION SUPPORT FROM THE INSTITUTE. THE FINAL ACCOUNTS WERE CLOSED OFF DURING THE FIRST HALF OF 2013. THE NEW YORK BRANCH CLOSED AT THE END OF 2012. UNDER CURRENT PLANS, THE MELBOURNE-AUSTIN BRANCH WILL BE CLOSED BY THE END OF 2014. PROVISION HAS BEEN MADE IN THE FINANCIAL STATEMENTS FOR REDUNDANCY AND SEVERANCE PAY DUE TO INSTITUTE STAFF MEMBERS AS A RESULT OF THESE CLOSURES. | |
| FORM 990, PART III | LABORATORY RESEARCH LEADING TO CLINICAL APPLICATIONS - LINE 4A | THE LUDWIG INSTITUTE FOR CANCER RESEARCH WAS FOUNDED OVER 40 YEARS AGO AS AN INTERNATIONAL NON-PROFIT RESEARCH INSTITUTE WITH A SINGLE FOCUS: IMPROVING THE UNDERSTANDING AND CONTROL OF CANCER. THE LUDWIG INSTITUTE'S SCIENTISTS UNDERTAKE PIONEERING BASIC RESEARCH AND FACILITATE THE TRANSLATION OF PROMISING CANCER DISCOVERIES INTO APPLICATIONS FOR HUMAN BENEFIT. LUDWIG TAKES RESPONSIBILITY FOR THE ENTIRE DISCOVERY CONTINUUM, FROM THE LABORATORY TO THE CLINIC. MAKING MEANINGFUL ADVANCES THAT WILL ULTIMATELY TRANSFORM CARE FOR CANCER PATIENTS IS THE MISSION THAT DRIVES THE LUDWIG INSTITUTE FORWARD. LUDWIG RESEARCH FOCUSES ON ENHANCING THE UNDERSTANDING OF CANCER ONSET AND PROGRESSION, AS WELL AS IDENTIFYING AND CHARACTERIZING TOOLS AND TARGETS FOR NEW PROGNOSTIC, DIAGNOSTIC AND THERAPEUTIC MODALITIES. THE LUDWIG INSTITUTE ENGAGES LEADING SCIENTISTS AND CLINICIANS IN AN INTEGRATED LABORATORY AND CLINICAL RESEARCH EFFORT TO CONFRONT THE GLOBAL CHALLENGE OF CANCER. SPECIFICALLY, LUDWIG LABORATORY RESEARCH SEEKS TO EXTEND THE KNOWLEDGE OF GENES, PROTEINS, CELLS AND CELLULAR PROCESSES INVOLVED IN CANCER ONSET AND PROGRESSION. THIS UNDERSTANDING OF THE MACROMOLECULAR AND CELLULAR ABERRATIONS IN CANCER THEN ALLOWS LUDWIG SCIENTISTS TO FURTHER THEIR LABORATORY WORK TO IDENTIFY, CHARACTERIZE AND EVALUATE NEW TOOLS AND TARGETS FOR THEIR POTENTIAL AS CLINICAL APPLICATIONS. ALL LABORATORY RESEARCH FINANCED BY LUDWIG IS CARRIED OUT BY THE INSTITUTE'S IN-HOUSE RESEARCH STAFF OR THROUGH RESEARCH COLLABORATIONS INVOLVING INSTITUTE STAFF AND EXTERNAL INVESTIGATORS. THE INSTITUTE EMPLOYED AROUND 550 SCIENTISTS, CLINICIANS AND SUPPORT PERSONNEL AT DECEMBER 31, 2012. THE LUDWIG INSTITUTE RECEIVES FUNDING OF APPROXIMATELY 60% OF ITS RESEARCH COSTS FROM LICR FUND, INC., A DELAWARE SUPPORTING ORGANIZATION DEDICATED TO MAINTAINING AN INVESTMENT PORTFOLIO AND PROVIDING FINANCIAL SUPPORT TO THE INSTITUTE. THIS DEDICATED FUNDING SOURCE GIVES LUDWIG INVESTIGATORS THE FREEDOM TO TACKLE INNOVATIVE LONG-TERM RESEARCH, AND ENCOURAGES AND ENABLES MULTIDISCIPLINARY TEAMS OF INVESTIGATORS TO TACKLE LARGER, MORE COMPLEX CANCER CHALLENGES. THE DEVELOPMENT, PROTECTION AND LICENSING OF INTELLECTUAL PROPERTY (IP) GENERATED BY RESEARCH DISCOVERIES AND TECHNOLOGY DEVELOPMENT IS FUNDAMENTAL TO LUDWIG'S COMMITMENT TO TRANSLATE ITS DISCOVERIES INTO APPLICATIONS FOR HUMAN BENEFIT. THE INSTITUTE PATENTS ITS IP TO ENSURE THAT LUDWIG DISCOVERIES ATTRACT INTEREST FROM COMMERCIAL PARTNERS WILLING TO INVEST IN THE SUCCESSFUL DEVELOPMENT OF THESE DISCOVERIES. LUDWIG ALSO MANAGES ITS IP PATENTS FOR PUBLIC BENEFIT. THIS MEANS THE IP IS MADE FREELY-AVAILABLE TO THE ACADEMIC RESEARCH COMMUNITY. INCOME FROM THESE ACTIVITIES FINANCED INSTITUTE RESEARCH EXPENDITURE AMOUNTING TO USD 4.1 MILLION. IN 2012, LUDWIG INVESTIGATORS PUBLISHED 334 PRIMARY RESEARCH ARTICLES AND 61 REVIEWS, BOOK CHAPTERS AND/OR COMMENTARIES. THESE PUBLICATIONS COVERED A RANGE OF CANCER RESEARCH DISCOVERIES IN THE FIELDS OF GENETICS, GENOMICS, CELL BIOLOGY, SIGNAL TRANSDUCTION, PROTEOMICS, IMMUNOLOGY, BIOINFORMATICS, AND TARGETED THERAPY DEVELOPMENT. IN 2012, 14 PATENTS WERE ISSUED AND 12 WERE FILED IN THE USA BASED ON LUDWIG DISCOVERIES, AND A FURTHER 4 NEW INTERNATIONAL PATENT APPLICATIONS WERE FILED AS WELL. THESE PATENTS COVER RESEARCH DISCOVERIES RELATING TO GROWTH FACTORS, CYTOKINES, SIGNALING MOLECULES, ANTIBODIES AND HUMAN TUMOR ANTIGENS. |
| FORM 990, PART III | CLINICAL RESEARCH - LINE 4B | LABORATORY RESEARCH ON ISOLATED CELLS AND MACROMOLECULES, WHILE CRITICAL, WILL NOT ALONE PRODUCE THE DIAGNOSTIC AND THERAPEUTIC TOOLS REQUIRED FOR CANCER CONTROL. TO FURTHER UNDERSTAND THE DISEASE AND THE BODY'S REACTION TO IT, AND TO EXPLORE THE THERAPEUTIC POTENTIAL OF DISCOVERIES, CLINICAL RESEARCH - THE ANALYSIS OF PATIENT SAMPLES AND POTENTIAL THERAPIES IN CLINICAL TRIALS - MUST ALSO BE CONDUCTED. RECOGNIZING THIS, THE LUDWIG INSTITUTE TAKES RESPONSIBILITY FOR THE ENTIRE DISCOVERY CONTINUUM, FROM THE LABORATORY TO THE CLINIC. LUDWIG BELIEVES THAT THE SAME SYSTEMATIC, INVESTIGATIVE RIGOR THAT YIELDED THE LABORATORY DISCOVERY IN THE FIRST PLACE SHOULD BE APPLIED IN EARLY-PHASE CLINICAL TRIALS TO ASSESS A DISCOVERY'S THERAPEUTIC POTENTIAL. THE INSTITUTE HAS, THEREFORE, COMMITTED THE RESOURCES AND MARSHALLED THE CAPABILITIES THAT ALLOW IT TO EVALUATE ITS PROMISING BASIC DISCOVERIES IN HUMAN CLINICAL STUDIES. THE LUDWIG INSTITUTE HAS LICENSING INTERACTIONS WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES THAT ALLOW IT TO OBTAIN PROPRIETARY INVESTIGATIONAL AGENTS AND EVALUATE WHETHER THESE AGENTS MIGHT COMPLEMENT THE THERAPEUTIC POTENTIAL OF THE INSTITUTE'S OWN DISCOVERIES. THE INSTITUTE'S INTERACTIONS WITH INDUSTRY ARE DESIGNED TO PROTECT ITS ETHOS AND INTEGRITY AND TO ENSURE THAT ITS DISCOVERIES ARE ACTIVELY PURSUED AS PROGNOSTIC, DIAGNOSTIC AND/OR THERAPEUTIC AGENTS FOR HUMAN BENEFIT. FOURTEEN INSTITUTE-SPONSORED CLINICAL TRIALS WERE ONGOING IN 2012. TWO ADDITIONAL STUDIES WERE MANAGED BY THE INSTITUTE, BUT NOT SPONSORED DIRECTLY. INSTITUTE INVESTIGATIONAL STUDY AGENTS WERE PROVIDED FOR AN ADDITIONAL 6 CLINICAL TRIALS SPONSORED AND MANAGED BY LOCAL ENTITIES. THESE 22 TRIALS WERE SUPPORTED BY 15 ACTIVE INSTITUTE REGULATORY DOSSIERS [9 INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS (USA), 3 DRUG MASTER FILES (DMF) AND 3 INVESTIGATIONAL MEDICINAL PRODUCT DOSSIERS, (EUROPEAN UNION)]. OVER THE YEAR, THE INSTITUTE MADE 6 NEW REGULATORY SUBMISSIONS AND 26 SUPPLEMENTAL SUBMISSIONS TO ITS ACTIVE REGULATORY DOSSIERS. |
| FORM 990, PARTS IV, LINE 12A AND XII, LINE 1 | THE INSTITUTE PREPARED CONSOLIDATED FINANCIAL STATEMENTS IN ACCORDANCE WITH SWISS GAAP FER. THE INSTITUTE PREPARED STATUTORY FINANCIAL STATEMENTS IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS. THE INSTITUTE PREPARED BRANCH FINANCIAL STATEMENTS IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS FOR THE FOLLOWING BRANCHES: BRUSSELS (BELGIUM), MELBOURNE-PARKVILLE (AUSTRALIA), MELBOURNE-AUSTIN (AUSTRALIA), OXFORD (UNITED KINGDOM), NEW YORK AND SAN DIEGO (UNITED STATES), SAO PAULO (BRAZIL), STOCKHOLM AND UPPSALA (SWEDEN). THE SUBMITTED RETURN 990 IS BASED ON THE STATUTORY FINANCIAL STATEMENTS IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS. THE FOLLOWING ACCOUNTING PRINCIPLES APPLY: - CONTRIBUTIONS ARE ACCOUNTED FOR ON THE CASH BASIS - INTEREST IS ACCOUNTED FOR ON THE ACCRUAL BASIS - EXTERNAL FUNDING RECEIVED FROM ANY OUTSIDE SOURCE, WHETHER OF CASH OR A NON-CASH NATURE, IS RECORDED IN THE INSTITUTE'S BOOKS OF ACCOUNT ON RECEIPT. EXTERNAL FUNDING RECEIVED IS TAKEN TO INCOME WHEN THE CORRESPONDING EXPENDITURE IS INCURRED. ANY UNSPENT INCOME IS DEFERRED TO FUTURE ACCOUNTING PERIODS. EXTERNAL FUNDING PLEDGED, BUT NOT RECEIVED WHERE EXPENDITURE HAS BEEN INCURRED, IS TAKEN TO ACCOUNT AS INCOME AND IS ACCOUNTED FOR AS A GRANTS RECEIVABLE PENDING RECEIPT. - LICENCE FEES AND ROYALTIES ARE ACCOUNTED FOR ON THE MODIFIED CASH BASIS. - EXPENDITURE ON EQUIPMENT AND OTHER ASSETS AND LEASEHOLD IMPROVEMENTS IS CHARGED IN FULL AGAINST REVENUE IN THE YEAR IT IS INCURRED. THE INSTITUTE PREPARED BRANCH FINANCIAL STATEMENTS IN ACCORDANCE WITH LOCAL ACCOUNTING REQUIREMENTS FOR THE BRANCHES IN NEW YORK (UNITED STATES) AND SAO PAULO (BRAZIL). THE INSTITUTE PREPARED FINANCIAL STATEMENTS IN ACCORDANCE WITH OFFICE OF MANAGEMENT AND BUDGET CIRCULAR A-133 FOR THE SAN DIEGO BRANCH (UNITED STATES). THE INSTITUTE MAINTAINS ACCOUNTING LEDGERS BY CURRENCY, BY BRANCH, AND BY FUNCTION. INSTITUTE CURRENCIES ARE: AUD, BRL, CHF, EUR, GBP, SEK AND USD. WHEN ANY EXPENDITURE/INCOME OR BALANCE SHEET TRANSACTIONS ARE RECORDED INTO THE ACCOUNTS, A NON-INSTITUTE CURRENCY IS CONVERTED INTO AN INSTITUTE CURRENCY AMOUNT USING THE RATE RULING AT THE DATE OF THE TRANSACTION. FOR THE PRODUCTION OF THE STATUTORY FINANCIAL STATEMENTS DENOMINATED IN USD, THE FOLLOWING PRINCIPLES APPLY: NON-USD CONTRIBUTION INCOME IS TRANSLATED INTO USD AT THE MONTHLY RATES AS PUBLISHED BY THE SWISS TAX AUTHORITIES. ALL OTHER NON-USD INCOME ITEMS ARE TRANSLATED INTO USD AT THE YEARLY AVERAGE OF THE MONTHLY RATES AS PUBLISHED BY THE SWISS TAX AUTHORITIES. NON-USD ASSETS AND LIABILITIES ARE TRANSLATED INTO USD AT THE RATES RULING AT THE END OF THE YEAR. THE RESULTING TRANSLATION ADJUSTMENTS ARE INCLUDED IN THE EXCESS OF EXPENDITURE OVER INCOME FOR THE YEAR. | |
| FORM 990, PART VI, SECTION A, LINE 2 | BUSINESS: DR ANDREW SIMPSON AND DR JONATHAN SKIPPER, OFFICERS OF LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, SERVED ON THE BOARD OF ANOTHER ORGANIZATION. BUSINESS: EDWARD A. MCDERMOTT JR AND DR JONATHAN SKIPPER, OFFICERS AND DIRECTORS OF THE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, ALSO SERVE ON THE BOARD OF ANOTHER ORGANIZATION. | |
| FORM 990, PART VI, SECTION A, LINE 3 | THE LUDWIG GROUP, INC., A 100% SUBSIDIARY OF THE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, PROVIDES MANAGEMENT AND ADMINISTRATIVE SERVICES TO THE LUDWIG INSTITUTE. SERVICES INCLUDE PROVIDING PAYROLL AND BENEFIT ADMINISTRATION TO SENIOR MANAGEMENT, ACCOUNTING SUPPORT AND PREPARING TAX RETURNS AND OTHER GOVERNMENT FILINGS. EDWARD A. MCDERMOTT JR, DIRECTOR AND PRESIDENT OF THE INSTITUTE IS COMPENSATED BY THE LUDWIG GROUP, INC. HIS COMPENSATION LISTED ON THE FORM 990, PART VII IS PAID BY THE LUDWIG GROUP, INC. EDWARD A. MCDERMOTT JR'S SERVICES TO THE INSTITUTE ARE BILLED TO THE INSTITUTE BY THE LUDWIG GROUP, INC. | |
| FORM 990, PART VI, SECTION A, LINE 6 | THE INSTITUTE IS ORGANIZED AS A SWISS NOT-FOR-PROFIT ORGANIZATION. FORTY-NINE OF THE SHARES ARE HELD BY THE TRUSTEES OF THE LICR CHARITABLE TRUST, A BERMUDA TRUST RECOGNIZED BY THE IRS AS AN EXEMPT SUPPORTING ORGANIZATION OF THE INSTITUTE UNDER SECTIONS 501(C)(3) AND 509(A)(3) OF THE INTERNAL REVENUE CODE, WHOSE PRIMARY PURPOSE IS TO ADMINISTER, DEVOTE AND APPLY ITS ASSETS TO FURTHER THE CHARITABLE AND SCIENTIFIC PURPOSES OF THE INSTITUTE. OF THE FORTY-NINE SHARES HELD BY THE TRUSTEES OF THE LICR CHARITABLE TRUST, THERE ARE THIRTY-EIGHT SCHEDULE A SHARES AND ELEVEN SCHEDULE B SHARES. PURSUANT TO THE PROVISIONS OF THE INSTITUTE'S STATUTES, THE MEMBERS OF THE BOARD OF DIRECTORS ARE REQUIRED TO BE SHAREHOLDERS. THE ELEVEN SCHEDULE B SHARES ARE AVAILABLE FOR THIS PURPOSE AND DURING THE TENURE OF THE BOARD MEMBER, THE TRUSTEES OF THE LICR CHARITABLE TRUST ASSIGN TO EACH BOARD MEMBER ONE SHARE. THE INSTITUTE'S OTHER OUTSTANDING SHARE IS HELD BY THE SWISS CONFEDERATION. SCHEDULE B SHARES WHICH ARE NOT ASSIGNED TO INDIVIDUAL BOARD MEMBERS ARE HELD BY THE LICR CHARITABLE TRUST. | |
| FORM 990, PART VI, SECTION A, LINE 7A | THE STATUTES OF THE INSTITUTE CONFER ON ITS SHAREHOLDERS THE AUTHORITY TO ELECT AND REMOVE MEMBERS OF THE BOARD OF DIRECTORS AND PARTICIPATE IN PROCEEDINGS, DELIBERATIONS, ELECTIONS AND VOTES AT SHAREHOLDER MEETINGS. THE SHARES DO NOT CONFER PROPRIETARY RIGHTS OR ANY ENTITLEMENT TO ANY SHARE OF THE INSTITUTE'S NET INCOME OR CAPITAL OR ANY OTHER ASSETS OWNED OR MANAGED BY THE INSTITUTE. THE INSTITUTE'S STATUTES PROHIBIT THE PAYMENT OF ANY DIVIDENDS OR DISTRIBUTION OF INCOME OR CAPITAL TO THE SHAREHOLDERS. | |
| FORM 990, PART VI, SECTION A, LINE 7B | THE SHAREHOLDERS HAVE THE POWER TO GRANT DISCHARGE TO THE MEMBERS OF THE BOARD OF DIRECTORS ANNUALLY AT THE SHAREHOLDERS ANNUAL MEETING FOR THEIR CONDUCT OF INSTITUTE BUSINESS. THE ANNUAL REPORT AND ANNUAL FINANCIAL STATEMENTS ARE SUBMITTED TO THE SHAREHOLDERS BY THE BOARD OF DIRECTORS FOR SHAREHOLDER APPROVAL. THE SHAREHOLDERS HAVE THE RIGHT TO MAKE RESOLUTIONS IN RESPECT OF MERGERS, DISSOLUTIONS OR LIQUIDATION OF THE COMPANY AND OF ANY CHANGE OF THE COMPANY'S REGISTERED OFFICE. | |
| FORM 990, PART VI, SECTION B, LINE 11B | THE INSTITUTE'S FORM 990 IS REVIEWED AT SEVERAL LEVELS. THE INSTITUTE'S ZURICH OFFICE SENIOR STAFF, THE DIRECTOR OF TAXES LOCATED IN NEW YORK, AND EXTERNAL TAX AND LEGAL COUNSEL REVIEW THE DRAFT FORM 990. FOLLOWING THESE REVIEWS, THE CHAIRPERSON OF THE AUDIT COMMITTEE REVIEWS THE DRAFT RETURN PRIOR TO PRESENTING IT TO THE AUDIT COMMITTEE FOR FURTHER REVIEW. THE FINAL DRAFT OF FORM 990 IS THEN PRESENTED TO THE INSTITUTE'S BOARD OF DIRECTORS PRIOR TO ITS SUBMISSION TO THE INTERNAL REVENUE SERVICE. | |
| FORM 990, PART VI, SECTION B, LINE 12C | THE INSTITUTE HAS BOTH A WRITTEN CONFLICT OF INTEREST POLICY AND CONFIDENTIAL DISCLOSURE POLICY. BOTH POLICIES WERE UPDATED IN 2012 TO REFLECT US NIH REQUIREMENTS. ANNUALLY, ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS AND ALL STAFF ARE REQUIRED TO DISCLOSE ANY CONFLICTS OF INTEREST. BOARD MEMBERS AND EXECUTIVE OFFICERS COMPLETE A CONFLICT OF INTEREST QUESTIONNAIRE. ALL OTHER STAFF MEMBERS COMPLETE A CONFIDENTIAL DISCLOSURE FORM. THE COMPLETED QUESTIONNAIRES OF THE MEMBERS OF THE BOARD OF DIRECTORS AND EXECUTIVE OFFICERS ARE REVIEWED BY THE COMPLIANCE AND RISK OFFICER. THOSE CONTAINING ANY DISCLOSURES OR POTENTIAL CONFLICTS OF INTEREST ARE REFERRED TO THE CHAIRPERSON OF THE AUDIT COMMITTEE AND, IF APPROPRIATE, TO THE AUDIT COMMITTEE. AT THE SAME TIME IT IS CONFIRMED TO THE AUDIT COMMITTEE CHAIRPERSON THAT THE OTHER INDIVIDUALS HAD NOT REPORTED ANY DISCLOSURES OR POTENTIAL CONFLICTS OF INTEREST. FOLLOWING THIS ANNUAL DISCLOSURE, IF A CONFLICT OF INTEREST IS SUBSEQUENTLY DEEMED TO EXIST, IT IS THE DUTY OF THE INDIVIDUAL WITH THE CONFLICT TO DISCLOSE IT. FOR ALL CASES WHERE A CONFLICT OF INTEREST EXISTS, THE MATTER IS RECORDED IN THE MINUTES OF THE MEETING OF THE AUDIT COMMITTEE OR THE BOARD. WHERE THE CONFLICT CONCERNS ANY BOARD OR COMMITTEE MEMBER, THE INDIVIUAL (S) IS (ARE) NOT PERMITTED TO PARTICIPATE IN ANY VOTE OR DELIBERATION ON THE MATTER NOR BE COUNTED IN DETERMINING THE EXISTENCE OF A QUORUM FOR THE PURPOSES OF ANY ACTION OF THE BOARD OR COMMITTEE CONSIDERING THE MATTER. THE ANNUAL DISCLOSURES BY STAFF ARE REVIEWED BY SENIOR MANAGEMENT AND ESCALATED AS NECESSARY. IN ADDITION, DURING THE YEAR, PRIOR TO INVOLVEMENT IN ACTIVITIES THAT COULD BE A POTENTIAL OR PERCEIVED CONFLICT OF INTEREST, INDIVIDUALS ARE REQUIRED TO PROVIDE A WRITTEN DESCRIPTION OF SUCH ACTIVITIES TO A COMMITTEE OF DISINTERESTED OFFICERS. ACTIVITIES DETERMINED TO BE A CONFLICT OF INTEREST THAT ARE NOT MANAGEABLE MAY NOT BE UNDERTAKEN BY THE INDIVIDUAL. FOR ACTIVITIES DETERMINED TO BE A CONFLICT OF INTEREST THAT ARE MANAGEABLE, DETAILS WILL BE SUBMITTED TO THE AUDIT COMMITTEE OF THE INSTITUTE BOARD OF DIRECTORS FOR APPROVAL. | |
| FORM 990, PART VI, SECTION B, LINES 15A AND 15B | THE COMPENSATION OF THE MEMBERS OF THE BOARD OF DIRECTORS, THE EXECUTIVE OFFICERS, KEY EMPLOYEES AND FORMER DIRECTORS AND OFFICERS WHO ARE RETAINED AS EMPLOYEES OR CONSULTANTS OF THE INSITUTE IS SUBJECT TO REVIEW BY THE INSTITUTE'S BOARD COMPENSATION COMMITTEE, WHICH CONSISTS OF INDEPENDENT MEMBERS OF THE BOARD. INDEPENDENT COMPENSATION CONSULTANTS PROVIDE COMPARABILITY SURVEYS TO THE COMMITTEE. ORGANIZATIONS SELECTED FOR PEER ANALYSIS IN THE COMPARABILITY SURVEYS ARE INTENDED TO CAPTURE COMPETITOR ORGANIZATIONS OF SIMILAR SIZE, REVENUE/OPERATING BUDGET AND INDUSTRY RELEVANCE TO LICR. THE STUDIES LAST TOOK PLACE IN SEPTEMBER 2010, AND WILL BE CONDUCTED EVERY THREE YEARS. MINUTES OF THE REVIEW AND DECISIONS MADE BY THE COMPENSATION COMMITTEE ARE KEPT AND, ONCE APPROVED, ARE SIGNED BY THE CHAIRPERSON AND THE SECRETARY TO THE BOARD. THE COMPENSATION COMMITTEE'S DECISIONS ARE REPORTED TO THE BOARD OF DIRECTORS AND RECORDED IN THE MINUTES OF THE BOARD MEETINGS, WHICH ARE KEPT FOR ALL BOARD MEETINGS. ONCE APPROVED BY THE BOARD AT A SUBSEQUENT MEETING, THE MINUTES OF MEETINGS ARE SIGNED BY THE CHAIRPERSON AND THE SECRETARY TO THE BOARD. | |
| FORM 990, PART VI, SECTION C, LINE 19 | THE INSTITUTE MAKES THE FOLLOWING DOCUMENTS AVAILABLE TO THE PUBLIC ON ITS COMPANY WEBSITE WWW.LUDWIGCANCERRESEARCH.ORG: - LICR ANNUAL RESEARCH HIGHLIGHTS REPORT - LICR ORGANIZATION TAX EXEMPT FORM 990 - LICR ANNUAL REPORT AND - LICR CONFLICT OF INTEREST POLICY - LICR CONFIDENTIAL DISCLOSURE POLICY. THE LICR ANNUAL REPORT INCLUDES THE STATUTORY FINANCIAL STATEMENTS OF THE INSTITUTE, WHICH HAVE BEEN PREPARED IN ACCORDANCE WITH THE PROVISIONS OF THE SWISS CODE OF OBLIGATIONS AND THE CONSOLIDATED FINANCIAL STATEMENTS OF THE INSTITUTE, WHICH HAVE BEEN PREPARED IN ACCORDANCE WITH SWISS-GAAP FER. GOVERNING DOCUMENTS ARE AVAILABLE ON REQUEST AT THE ADMINISTRATIVE OFFICES IN NEW YORK AND ZURICH, SWITZERLAND. | |
| FORM 990, PART VII | AS PART OF THE ANNUAL PREPARATION OF THE FORM 990, THE CHIEF FINANCIAL OFFICER ASKS ALL BOARD OF DIRECTORS AND EXECUTIVE OFFICERS FOR THEIR ESTIMATE OF HOURS WORKED FOR THE INSTITUTE AND THE RELATED ORGANIZATIONS. (SEE PART VII) FOR HOURS DEVOTED TO RELATED ORGANIZATIONS.) THE RELATED ORGANIZATIONS REPORT THE RESPECTIVE COMPENSATION FIGURES TO THE INSTITUTE AND PROVIDE COPIES OF THE SUBMITTED W-2 RETURNS/1099 RETURNS. | |
| FORM 990, PART IX | CONSISTENT WITH THE FINANCIAL STATEMENTS PREPARED IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS, FUNCTIONAL EXPENSES REPORTED ON FORM 990, PART IX INCLUDE UNREALIZED APPRECIATION/ DEPRECIATION AND FOREIGN EXCHANGE GAINS/ LOSSES. | |
| FORM 990, PART XI, LINE 9 | FOREIGN EXCHANGE DIFFERENCE ON SHARE CAPITAL AND LEGAL RESERVE. |
| Software ID: | |
| Software Version: |